Syndax To Announce Topline Results From Pivotal AUGMENT-101 Trial Of Revumenib In Relapsed/Refractory KMT2Ar Acute Leukemia And Host An Investor Call on Oct. 2
Portfolio Pulse from Benzinga Newsdesk
Syndax Pharmaceuticals is set to announce topline results from its pivotal AUGMENT-101 trial of Revumenib in relapsed/refractory KMT2Ar acute leukemia. The company will also host an investor call on October 2.
September 29, 2023 | 8:06 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
The announcement of topline results from Syndax's AUGMENT-101 trial could significantly impact the company's stock price, depending on the outcome of the trial.
The announcement of topline results from a pivotal trial is a significant event for any pharmaceutical company. Positive results could boost the company's stock price, while negative results could have the opposite effect. The investor call could also provide further insights into the company's plans and outlook, potentially influencing the stock price.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100